CommentaryABSTRACT
This article provides a comprehensive review of carbapenem-resistant Enterobacteriaceae (CRE). Carbapenem-resistant Enterobacteriaceae have emerged, which confer broad resistance to most ß-lactam antibiotics including last-line carbapenems. Infection with Carbapenem-resistant Enterobacteriaceae is emerging as an emerging and serious global public health threat. Carbapenem-resistant Enterobacteriaceae is widely spread and is now a major factor in morbidity and mortality in health-care settings. Continued research is desperately needed to determine the most appropriate treatment for serious Carbapenem-resistant Enterobacteriaceae infections.
Keywords: Carbapenemases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Resistant Infections; Treatment
Introduction
Respiratory infection is one of the most common diseases in the world, with high incidence and mortality. Enterobacteriaceae is the most clinically important gram-negative pathogenic bacteria, which are increasingly being reported worldwide. Antimicrobial resistance is globally recognized as one of the greatest threats to public health. For years, carbapenems have been used successfully to treat infections due to resistant Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae. However, recently Carbapenem-resistant Enterobacteriaceae have emerged, which confer broad resistance to most ß-lactam antibiotics including lastline carbapenems. Carbapenem-resistant Enterobacteriaceae refers to Enterobacteriaceae that are resistant to any drug of ertapenem, Doripenem, imipenem, meropenem, or enterobacteriaceae that produce carbapenemase. Infection with Carbapenem-resistant Enterobacteriaceae is emerging as an important challenge in healthcare settings and a growing concern worldwide, it is very easy to spread in patients with long-term hospitalization or low immunity, leading to nosocomial infection, and may even cause a small- or large-scale outbreak [1-3]. Most Enterobacteriaceae belong to the normal flora in the intestinal tract and can become opportunistic pathogens once the body’s immunity declines. Enterobacteriaceae obtain genetic material mainly by horizontal gene transfer mediated by plasmids and transposons [4] Carbapenem-resistant Enterobacteriaceae can cause a number of serious infection types (such as pneumonia, abdominal cavity infection, urinary tract infections, Bloodstream infection, skin and soft tissue infection, central nervous system infection, and device-associated infections) or asymptomatic colonization, among which Ventilator-associated pneumonia (VAP) was the most common [5]. Severe pneumonia has always been a common respiratory disease, which can endanger life. Statistics [6] show that infectious diseases account for 30% of all deaths worldwide, with severe pneumonia leading the way. Carbapenem-resistant Enterobacteriaceae infection was reported in 68.8% of patients with hospital acquired bacterial pneumonia [7]. Consistent mortality rates of 40-50% are observed among inpatients with infections caused by CRE in hospitals worldwide, while the mortality rate from CRE infection in pneumonia patients is as high as 60% [8]. Carbapenem-resistant Enterobacteriaceae infection is a very difficult problem in clinical practice.
Risk Factors of Acquisition of CRE Infection
There are a number of factors that predispose persons to infections by CRE. Exposure to these resistant organisms can cause serious infections in patients with the following reported risk factors: immune-suppression, advanced age, admission to intensive care unit (ICU), mechanical ventilation, previous exposure to antimicrobials, organ or stem-cell transplantation and prolonged hospital stays. Healthcare associated infections caused by CRE, mainly Klebsiella pneumoniae, have been encountered most commonly in ventilator-associated pneumonia, bacteremia, urinary tract and surgical site infections. Growing evidence suggests early detection of CRE-colonized patients on admission to long-term care facilities may help to prevent institutional outbreaks and limit regional spread of this emerging public health threat. Respiratory disease is one of the risk factors for CRE infection, probably because a variety of bacteria grow in the respiratory tract and maintain a dynamic balance in the body. Elderly patients with respiratory diseases have low immunity and are vulnerable to infection. Moreover, most patients with respiratory diseases have a history of invasive operation. When tracheotomy or endotracheal intubation is performed, the respiratory mucosa will be damaged, resulting in a variety of complications. Some bacteria are easy to form biofilm in the open airway, which leads to abnormal expression of outer membrane pore protein and bacterial drug resistance. In particular, frequent aerosol inhalation and other operations change the airway environment, requiring frequent contact with patients by medical staff, which makes patients susceptible to colonization and infection by multi-resistant bacteria.
Prevention and Control measures for CRE Infections
2.1 There are reports which suggest that overuse of carbapenems is closely related to the incidence of CRE infection, and unreasonable use of carbapenems can easily induce bacterial resistance and spread [9]. One of the chief difficulties in the treatment of CRE is the excessive use of antibiotics, not only those acquired by the community but also in hospitals. On the one hand, the use of broad-spectrum antibiotics can kill the sensitive bacteria, and the resistant bacteria can survive and become the dominant growth, thus increasing the probability of CRE infection. On the other hand, drug resistance may occur due to the change of drug binding sites after drug use, resulting in carbapenemases and other drug resistance mechanisms [10]. Growing evidence suggests that carbapenem-resistant Gram-negative bacteria are sufficient to develop in the intestinal flora of intensive care patients just a few days of application of carbapenems antibiotics [11]. Therefore, it is necessary to strengthen the supervision and management of clinical application of carbapenems, and strictly implement the classification of antibiotics and the management of doctors’ prescribing rights, limiting the over-use and abuse of antibiotics in humans and agriculture.
Standardized Collection and Correct Interpretation of Microbial Test Reports
Specimens should be collected before antibiotic treatment,
sterile site specimens should be collected as far as possible and
microbial reports should be correctly interpreted, eliminating
contamination and colonization and avoiding unnecessary use
of antibiotics. Therefore, clinical microbiology laboratories at all
levels of medical institutions should establish the ability to receive
and process microbial specimens within 24 hours.
There are reports which suggest that that patient carrying other
multidrug-resistant bacteria are mostly in serious and complex
conditions, with low immunity and relatively long stay in intensive
care units, leading to the development of CRE. Therefore, it is
necessary to strengthen the contact and isolation of MDR-resistant
bacteria to avoid the spread of MDR-resistant bacteria in hospitals.
Hand hygiene is the simplest, most effective, most convenient and
economical method to control the infection in hospitals, which can
significantly reduce the incidence of CRE infection. Mobile water
sinks, non-contact faucets, hand sanitizers, hand drying facilities,
quick-drying hand disinfectants, and related charts can reduce the
colonization rate of CRE [12].
Studies show that the wash basin and its surrounding
environment are seriously polluted, which is an important source of
CRE pollution. Therefore, medical institutions should pay attention
to the cleaning, disinfection and management of the location of
the sink in the diagnosis and treatment area, taking anti-splash
measures. Symptomatic colonized patients can become potential
sources of infection. The significance of active screening lies in early
identification of CRE colonized patients so that timely isolation
measures can be taken to reduce the risk of transmission. Stool is
the best specimen for active screening, and if not readily available,
a rectal swab is taken. If the patient has a definite history of CRE
infection, specimens from the infected site should be screened
again. Patients with positive initial screening and hospitalized for
less than 30 days do not need further screening, while patients
hospitalized for more than 30 days were screened once a month.
Those who have been screened negative for the first time should be
screened regularly, either once a week or every two weeks, or twice
a week, depending on the severity of the outbreak. Health care
facilities should implement isolation of all CRE infected/colonized
persons. Isolation refers not only to the establishment of physical
spatial barriers, but also to the strict enforcement of isolation
measures.
Treatment Options for CRE Infections
There are numerous different types of carbapenemase
enzymes, each conferring varying spectrums of resistance. In general, the presence of a carbapenemase confers broad resistance
to most ß-lactam antibiotics including penicillins, cephalosporins,
and the monobactam aztreonam (excluding metallo-β-lactamases
[MBLs] and oxacillinases [OXAs]) [13]. At present, the main drugs
for the treatment of CRE in the world are polymyxins, Tigecycline,
fosfomycin, Ceftazidime-Avibatam and aminoglycoside antibiotics.
Polymyxins and tigecycline were highly sensitive to CRE in vitro
and were not affected by the type of carbapenemases produced
by bacteria. Due to heterogeneous drug resistance and positive
correlation between dose and renal toxicity, polymyxins are
often used in combination with other antibacterial agents. The
conventional dose of tigecycline is difficult to reach sufficient
concentration in the areas including the blood flow and alveolar
lining fluid, so it is often necessary to increase the dose and use
it in combination with other drugs. Ceftazidime-avibactam lacks
effective antibacterial activity against metalloenzyme-producing
CRE, so it may be an important choice for the treatment of nonmetalloenzyme-
producing CRE infection. The most common
adverse drug reactions of Ceftazidime-avibactam in trials were
vomiting, nausea, constipation, and anxiety [14].
Combination therapy for CRE infections may decrease
mortality compared with monotherapy. Benefits of combination
therapy include reduction of initial inappropriate antimicrobial
therapy, potential synergistic effects, and suppression of emerging
resistance [15]. For patients who are critically ill or with deep-seated
infections, consider empiric and antibiogram-directed combination
therapy with 3 drugs, basing on antimicrobial sensitivity results.
Polymyxins may be most effective as part of a combination for
serious CRE infections [15,16].
Conclusion
In summary, the burden of carbapenem-resistant Enterobacteriaceae is increasing rapidly worldwide. CRE is widely spread and is now a major factor in morbidity and mortality in health-care settings. The results at present are still not good, especially in elderly patients with a history of CRE infection. The extremely high mortality rates of patients with CRE infections have driven efforts to prevent the acquisition and spread of these bacteria in hospitals. Although the above measures are simple, they can prevent the spread of CRE to some extent. However, continued research is desperately needed to determine the most appropriate treatment for serious CRE infections.
References
- Schwaber MJ, Carmeli Y (2008) Carbapenem-resistant Enterobacteriaceae: A potential threat. J Am Med Assoc 300(24): 2911-2913.
- Nordmann P, Naas, T, Poirel L (2011) Global spread ofcarbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17(10): 1791-1798.
- Ola H Moghnia, Vincent O Rotimi, Noura A Al-Sweih (2021) Monitoring antibiotic resistance profiles of faecal isolates of Enterobacteriaceae and the prevalence of carbapenem-resisant isolates carbapenem-resistant isolates among food handlers in Kuwait. Journal of antimicrobial Resistance 25: 370-376.
- Patrice N, Thierry N, Laurent P (2011) Global Spread of Carbapenemase-Producing Enterobacteriaceae. Emerging Infectious Diseases 17(10): 1791-1798.
- De Maio CarrilhoCM, de OliveiraLM, GauderetoJ, Juliana Gaudereto, Jamile S Perozin, Mariana Ragassi Urbano, et al. (2016) A prospective study of treatment of Carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 16(1): 629.
- Brown SM, Dean NC (2011) Defining Severe Pneumonia. Clinics In Chest Medicine 32(3): 469-479.
- Pang F, Jia XQ, Zhao QG, et al. (2018) Factors Associated to Prevalence and Treatment of Carbapenem-resistant Enterobacteriaceae Infections: a Seven Years Retrospective Study In Three Tertiary Care Hospitals. Ann Clin Microbiol Antimicrob 17(1): 1-8.
- Carrilho CMD DM, Oliveira LMD, Gaudereto J, Jamile S. Perozin,3 Mariana Ragassi Urbano, et al. (2016) A Prospective Study of Treatment of Carbapenem-resistant Enterobacteriaceae Infections and Risk Factors Associated with Outcome. Bmc Infectious Diseases 16(1): 1-9.
- Prakobsrikul N, Malathum K, Santanirand P, Supatat Chumnumwat 1, Pongsathorn Piebpien, et al. (2019) Correlation between antimicrobial consumption and the prevalence of carbapenem-resistant Escherichia coli and carbapenem-resistant Klebsiella pneumoniae at a university hospital in Thailand. J Clin Pharm Ther 44(2): 292-299.
- Suk KJ, Jongyoun Y, Kyung KM, Soon Ok Lee 1, Jeong Eun Lee, et al. (2019) Prevalence and Risk Factors of Carbapenem-resistant Enterobacteriaceae Acquisition in An Emergency Intensive Care Unit in a Tertiary Hospital in Korea: a Case-Control Study. Journal Of Korean Medical Science 34(18): e140.
- Kim T, Chong Y P, Park S Y, Min-Hyok Jeon 4, Eun Joo Choo, et al. (2014) Risk Factors for Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients: a Multicenter Study In Korea [J]. Diagn Microbiol Infect Dis 78(4): 457-461.
- Viale P, Tumietto F, Giannella M, M Bartoletti, S Tedeschi et al. (2015) Impact of a hospital-wide multifaceted programme for reducing Carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect 21(3): 242-247.
- Nordmann P, Dortet L, Poirel L (2012) Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18(5): 263-272.
- Actavis plc (2015) Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM). 2015. Feb 25.
- Petrosillo N, Giannella M, Lewis R (2013) Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 11(2): 159-177.
- Lynch JP 3rd, Clark NM, Zhanel GG (2013) Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum beta-lactamases and carbapenemases). Expert Opin Pharmacother 14(2): 199-210.
